{"id":3118,"date":"2015-06-04T04:11:00","date_gmt":"2015-06-04T08:11:00","guid":{"rendered":"https:\/\/isologicradiopharm.ca\/piramal-annonce-un-partenariat-strategique-avec-isologic\/"},"modified":"2025-05-13T23:08:30","modified_gmt":"2025-05-14T03:08:30","slug":"piramal-annonce-un-partenariat-strategique-avec-isologic","status":"publish","type":"post","link":"https:\/\/isologicradiopharm.ca\/en\/piramal-annonce-un-partenariat-strategique-avec-isologic\/","title":{"rendered":"Piramal Announces Strategic Partnership with ISOLOGIC"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ custom_margin=”0px||||false|false” custom_padding=”0px|||0px|false|false” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.4″ text_font_size=”16px” text_line_height=”1.9em” background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” hover_enabled=”0″ global_colors_info=”{}” theme_builder_area=”post_content” sticky_enabled=”0″]BOSTON, June 4, 2015 \u2013<\/p>\n

Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals today announce the companies have entered into a strategic partnership and licensing agreement to provide ISOLOGIC with exclusive rights to manufacture, market, and distribute Neuraceq (florbetaben F18 injection), a radiopharmaceutical tracer for positron emitting tomography (PET) imaging throughout Canada. The agreement will allow Piramal Imaging to gain access to the largest commercial network of cyclotrons for PET tracer production in the country.<\/p>\n

Alzheimer\u2019s disease, a condition that slowly destroys memory and cognitive abilities, currently affects more than 747,000 people in Canada according to the Canadian Institutes of Health Research. The total number of those affected is expected to surpass one million people in the country by 2031.1<\/sup><\/p>\n

\u201cWe are confident that our commitment to providing access to diagnostic beta-amyloid radiotracers in Canada will have a significant impact on the management of patients suspected of having Alzheimer\u2019s disease,\u201d said Andr\u00e9 Gagnon, President at ISOLOGIC. \u201cIn the context of evidence-based medicine, the introduction of Neuraceq in the marketplace will offer a new clinical evaluation method for patients, physicians and caregivers alike in the diagnosis and management of Alzheimer\u2019s disease. It could potentially help identify more efficacious interventions to help prevent, halt or slow down this terrible disease.\u201d<\/p>\n

The technical transfer of the manufacturing and quality control (QC) processes to ISOLOGIC has already been initiated and the company is currently exploring regulatory pathways and clinical trial applications in Canada to provide access to Neuraceq in ongoing and future clinical trials. ISOLOGIC intends to apply for a marketing authorization with Health Canada in the coming months.<\/p>\n

\u201cPiramal Imaging continues to expand the manufacturing and distribution network to bring Neuraceq into new markets,\u201d said Friedrich Gause, Chief Operating Officer at Piramal Imaging. \u201cThe partnership with ISOLOGIC demonstrates our commitment to further expanding our global presence and increasing access to beta-amyloid PET scanning for imagers and referring physicians to advance the accuracy of clinical diagnosis in Alzheimer\u2019s disease.\u201d<\/p>\n

Until today, an estimated 20-30% of patients with dementia have been misdiagnosed and often experienced extended diagnostic episodes before receiving a clinical diagnosis.2<\/sup> A definitive diagnosis of Alzheimer\u2019s disease could only be made after death based on autopsy findings of beta-amyloid plaques GLO\/FBB\/0515\/0066 and neurofibrillary tangles in the brain. Today, a comprehensive clinical evaluation in combination with in-vivo biomarkers, such as beta-amyloid PET imaging, improves the diagnostic accuracy while the patient is still alive, allowing for optimal patient management and better outcomes.<\/p>\n

About Neuraceq (florbetaben F18 injection)<\/p>\n

Indication
\nThis medicinal product is for diagnostic use only.<\/p>\n

Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of betaamyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer\u2019s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no neuritic plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, please refer to the US package insert.<\/p>\n

Important Safety Information
\nNeuraceq cannot be used to diagnose Alzheimer\u2019s disease and it cannot predict a patient\u2019s predisposition for beta-amyloid neuritic plaque development in the future. Neuraceq images should only be interpreted by readers trained in the interpretation of PET images with florbetaben F18 injection. Following training, image-reading errors (including false positive or false negative interpretation of Neuraceq images) may still occur. Additional interpretation errors may occur due to image noise, brain atrophy with a thinned cortical ribbon, or image blurs.<\/p>\n

Administration of Neuraceq, as with other radiopharmaceuticals, results in a low amount of ionizing radiation exposure. Safety precautions should be taken to ensure healthcare providers and patients do not receive unintentional radiation exposure from Neuraceq.<\/p>\n

Most common adverse events
\nThe most common side effects observed in clinical trials were injection site reaction and injection site pain.<\/p>\n

About Piramal Imaging SA<\/strong><\/p>\n

Piramal Imaging SA, a division of Piramal Enterprises, Ltd., was established in 2012 with the acquisition of Bayer Pharma AG’s molecular imaging research and development portfolio. By developing novel PET tracers for molecular imaging, Piramal Imaging is focusing on a key area of \u200b\u200bmodern medicine. Piramal Imaging strives to be a leader in the field of molecular imaging by developing innovative products that improve the early detection and characterization of chronic and life-threatening diseases, leading to better treatment outcomes and a higher quality of life. For more information, visit\u00a0<\/span>www.piramal.com\/imaging<\/span><\/a>.<\/p>\n

About ISOLOGIC Innovative Radiopharmaceuticals<\/strong><\/p>\n

ISOLOGIC Innovative Radiopharmaceuticals (ISOLOGIC) is a Canadian radiopharmaceutical company dedicated to nuclear medicine and the science of radiopharmaceutical production. ISOLOGIC\u2019s commitment to these fields includes cyclotron centers and SPECT and PET radiopharmaceutical manufacturing facilities throughout Canada. Utilizing significant experience, expertise to provide its customers and patients with reliable, safe and high quality radiopharmaceutical products and services.<\/p>\n

ISOLOGIC\u2019s network of SPECT & PET radiopharmacies positions the company to service Group Purchase Organizations, regional health care systems, as well as stand-alone Independant Healthcare Facilities, and clinics and hospitals. ISOLOGIC\u2019s open formulary of radiopharmaceutical drugs and medical devices provides the flexibility of choice, providing its customers with access to all radiopharmaceuticals, having Health Canada market authorization.<\/p>\n

Sources of Information<\/strong><\/p>\n

    \n
  1. Canadian Institutes of Health Research. 2013. Alzheimer\u2019s Research in Canada.\u00a0<\/span>http:\/\/www.alzheimer.ca<\/a><\/span><\/li>\n
  2. Speechly CM, Bridges-Webb C, Passmore E. The pathway to dementia diagnosis. Med J Aust. 2008;189(9):487-9.<\/li>\n<\/ol>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

    BOSTON, June 4, 2015 \u2013 Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals today announce the companies have entered into a strategic partnership and licensing agreement to provide ISOLOGIC with exclusive rights to manufacture, market, and distribute Neuraceq (florbetaben F18 injection), a radiopharmaceutical tracer for positron emitting tomography (PET) imaging throughout Canada. The agreement will allow […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[fusion_builder_container admin_label=\"\" hundred_percent=\"no\" equal_height_columns=\"no\" menu_anchor=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"http:\/\/s724396055.online-home.ca\/wp-content\/uploads\/2016\/11\/post_bg.jpg\" background_position=\"center center\" background_repeat=\"no-repeat\" fade=\"no\" background_parallax=\"none\" enable_mobile=\"no\" parallax_speed=\"0.3\" video_mp4=\"\" video_webm=\"\" video_ogv=\"\" video_url=\"\" video_aspect_ratio=\"16:9\" video_loop=\"yes\" video_mute=\"yes\" video_preview_image=\"\" border_color=\"\" border_style=\"solid\" margin_top=\"\" margin_bottom=\"\" padding_top=\"150px\" padding_right=\"\" padding_bottom=\"90px\" padding_left=\"\" type=\"legacy\"][fusion_builder_row][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" margin_top=\"\" margin_bottom=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"true\" spacing_right=\"\"][\/fusion_builder_column][fusion_builder_column type=\"2_3\" layout=\"2_3\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"#ffffff\" background_image=\"\" background_position=\"left top\" undefined=\"\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"50px\" padding_right=\"50px\" padding_bottom=\"30px\" padding_left=\"50px\" margin_top=\"\" margin_bottom=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\" spacing_right=\"\"][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

    PIRAMAL IMAGING ANNONCE UN PARTENARIAT STRAT\u00c9GIQUE AVEC ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS POUR LA COMMERCIALISATION EXCLUSIVE DE NEURACEQ AU CANADA<\/h3>\n[\/fusion_text][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"true\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\"][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"true\" spacing_right=\"\"][\/fusion_builder_column][fusion_builder_column type=\"2_3\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\" spacing_right=\"\"][fusion_imageframe image_id=\"769\" style_type=\"none\" stylecolor=\"\" hover_type=\"zoomin\" bordersize=\"\" bordercolor=\"\" borderradius=\"\" align=\"none\" lightbox=\"yes\" gallery_id=\"\" lightbox_image=\"\" alt=\"\" link=\"\" linktarget=\"_self\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]http:\/\/s724396055.online-home.ca\/wp-content\/uploads\/2017\/06\/piramal-pr.jpg[\/fusion_imageframe][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"true\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\"][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"true\" spacing_right=\"\"][\/fusion_builder_column][fusion_builder_column type=\"2_3\" layout=\"2_3\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"#ffffff\" background_image=\"\" background_position=\"left top\" undefined=\"\" background_repeat=\"no-repeat\" border_color=\"#25afb4\" border_style=\"solid\" border_position=\"bottom\" padding_top=\"50px\" padding_right=\"50px\" padding_bottom=\"50px\" padding_left=\"50px\" margin_top=\"\" margin_bottom=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"false\" border_sizes_bottom=\"8\" first=\"false\" spacing_right=\"\"][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

    BOSTON, le 4 juin 2015<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nPiramal Imaging SA et ISOLOGIC Innovative Radiopharmaceuticals annoncent aujourd'hui que les soci\u00e9t\u00e9s ont conclu un partenariat strat\u00e9gique et un accord de licence pour fournir \u00e0 ISOLOGIC les droits exclusifs de fabrication, de commercialisation et de distribution de Neuraceq (injection de florbetaben F18), un traceur radiopharmaceutique pour la tomographie par \u00e9mission de positrons (TEP) l'imagerie partout au Canada. L'accord permettra \u00e0 Piramal Imaging d'acc\u00e9der au plus grand r\u00e9seau commercial de cyclotrons pour la production de traceurs TEP du pays.\n\nLa maladie d'Alzheimer, une maladie qui d\u00e9truit lentement la m\u00e9moire et les capacit\u00e9s cognitives, touche actuellement plus de 747 000 personnes au Canada selon les Instituts de recherche en sant\u00e9 du Canada. Le nombre total de personnes touch\u00e9es devrait d\u00e9passer le million de personnes dans le pays d'ici 2031.1\n\n\u00ab Nous sommes convaincus que notre engagement \u00e0 fournir un acc\u00e8s aux radiotraceurs b\u00eata-amylo\u00efdes diagnostiques au Canada aura un impact significatif sur la prise en charge des patients suspect\u00e9s d'\u00eatre atteints de la maladie d'Alzheimer \u00bb, a d\u00e9clar\u00e9 Andr\u00e9 Gagnon, pr\u00e9sident d'ISOLOGIC. \u00ab Dans le contexte de la m\u00e9decine factuelle, l'introduction de Neuraceq sur le march\u00e9 offrira une nouvelle m\u00e9thode d'\u00e9valuation clinique pour les patients, les m\u00e9decins et les soignants dans le diagnostic et la gestion de la maladie d'Alzheimer. Cela pourrait potentiellement aider \u00e0 identifier des interventions plus efficaces pour aider \u00e0 pr\u00e9venir, arr\u00eater ou ralentir cette terrible maladie.\n\nLe transfert technique des processus de fabrication et de contr\u00f4le de la qualit\u00e9 (CQ) \u00e0 ISOLOGIC a d\u00e9j\u00e0 \u00e9t\u00e9 initi\u00e9 et la soci\u00e9t\u00e9 explore actuellement les voies r\u00e9glementaires et les applications d'essais cliniques au Canada pour donner acc\u00e8s \u00e0 Neuraceq dans les essais cliniques en cours et futurs. ISOLOGIC a l'intention de d\u00e9poser une demande d'autorisation de mise sur le march\u00e9 aupr\u00e8s de Sant\u00e9 Canada dans les prochains mois.\n\n\u00ab Piramal Imaging continue d'\u00e9tendre le r\u00e9seau de fabrication et de distribution pour amener Neuraceq sur de nouveaux march\u00e9s \u00bb, a d\u00e9clar\u00e9 Friedrich Gause, directeur de l'exploitation chez Piramal Imaging. \u00ab Le partenariat avec ISOLOGIC d\u00e9montre notre engagement \u00e0 \u00e9tendre davantage notre pr\u00e9sence mondiale et \u00e0 accro\u00eetre l'acc\u00e8s \u00e0 la TEP b\u00eata-amylo\u00efde pour les imageurs et les m\u00e9decins traitants afin d'am\u00e9liorer la pr\u00e9cision du diagnostic clinique de la maladie d'Alzheimer.\n\nJusqu'\u00e0 aujourd'hui, on estime que 20 \u00e0 30\u00a0% des patients atteints de d\u00e9mence ont \u00e9t\u00e9 mal diagnostiqu\u00e9s et ont souvent connu des \u00e9pisodes de diagnostic prolong\u00e9s avant de recevoir un diagnostic clinique.2 Un diagnostic d\u00e9finitif de la maladie d'Alzheimer ne peut \u00eatre pos\u00e9 qu'apr\u00e8s le d\u00e9c\u00e8s sur la base des r\u00e9sultats d'autopsie des plaques b\u00eata-amylo\u00efdes. GLO\/FBB\/0515\/0066 et enchev\u00eatrements neurofibrillaires dans le cerveau. Aujourd'hui, une \u00e9valuation clinique compl\u00e8te en combinaison avec des biomarqueurs in vivo, tels que l'imagerie TEP b\u00eata-amylo\u00efde, am\u00e9liore la pr\u00e9cision du diagnostic pendant que le patient est encore en vie, permettant une prise en charge optimale du patient et de meilleurs r\u00e9sultats.\n\n\u00c0 propos de Neuraceq (injection de florbetaben F18)\n\nIndication\nCe m\u00e9dicament est \u00e0 usage diagnostique uniquement.\n\nNeuraceq est un radiopharmaceutique indiqu\u00e9 pour l'imagerie par tomographie par \u00e9mission de positrons (TEP) de la densit\u00e9 de la plaque neuritique b\u00eata-amylo\u00efde dans le cerveau de patients adultes atteints de troubles cognitifs qui sont \u00e9valu\u00e9s pour la maladie d'Alzheimer (MA) et d'autres causes de troubles cognitifs. Neuraceq doit \u00eatre utilis\u00e9 conjointement avec une \u00e9valuation clinique. Une scintigraphie n\u00e9gative indique des plaques s\u00e9niles clairsem\u00e9es ou inexistantes, ce qui n'est pas compatible avec un diagnostic de MA. Pour conna\u00eetre les limites de l'interpr\u00e9tation d'un scan positif, veuillez consulter la notice d'accompagnement aux \u00c9tats-Unis.\n\nInformations importantes sur la s\u00e9curit\u00e9\nNeuraceq ne peut pas \u00eatre utilis\u00e9 pour diagnostiquer la maladie d'Alzheimer et il ne peut pas pr\u00e9dire la pr\u00e9disposition d'un patient au d\u00e9veloppement futur de la plaque neuritique b\u00eata-amylo\u00efde. Les images Neuraceq ne doivent \u00eatre interpr\u00e9t\u00e9es que par des lecteurs form\u00e9s \u00e0 l'interpr\u00e9tation des images TEP avec injection de florbetaben F18. Apr\u00e8s la formation, des erreurs de lecture d'images (y compris l'interpr\u00e9tation faussement positive ou faussement n\u00e9gative des images Neuraceq) peuvent encore se produire. Des erreurs d'interpr\u00e9tation suppl\u00e9mentaires peuvent survenir en raison du bruit de l'image, de l'atrophie c\u00e9r\u00e9brale avec un ruban cortical aminci ou des images floues.\n\nL'administration de Neuraceq, comme d'autres radiopharmaceutiques, entra\u00eene une faible exposition aux rayonnements ionisants. Des pr\u00e9cautions de s\u00e9curit\u00e9 doivent \u00eatre prises pour s'assurer que les prestataires de soins de sant\u00e9 et les patients ne re\u00e7oivent pas d'exposition involontaire aux rayonnements de Neuraceq.\n\n\u00c9v\u00e9nements ind\u00e9sirables les plus courants\nLes effets ind\u00e9sirables les plus fr\u00e9quemment observ\u00e9s dans les essais cliniques \u00e9taient la r\u00e9action au site d'injection et la douleur au site d'injection.\n\n[\/fusion_text][fusion_separator style_type=\"none\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" top_margin=\"40px\" border_size=\"0\" alignment=\"center\" \/][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

    \u00c0 propos de Piramal Imaging SA<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nPiramal Imaging SA, une division de Piramal Enterprises, Ltd., a \u00e9t\u00e9 cr\u00e9\u00e9e en 2012 avec l'acquisition du portefeuille de recherche et d\u00e9veloppement en imagerie mol\u00e9culaire de Bayer Pharma AG. En d\u00e9veloppant de nouveaux traceurs TEP pour l'imagerie mol\u00e9culaire, Piramal Imaging se concentre sur un domaine cl\u00e9 de la m\u00e9decine moderne. Piramal Imaging s'efforce d'\u00eatre un leader dans le domaine de l'imagerie mol\u00e9culaire en d\u00e9veloppant des produits innovants qui am\u00e9liorent la d\u00e9tection pr\u00e9coce et la caract\u00e9risation des maladies chroniques et potentiellement mortelles, conduisant \u00e0 de meilleurs r\u00e9sultats th\u00e9rapeutiques et \u00e0 une meilleure qualit\u00e9 de vie. Pour plus d'informations, rendez-vous sur www.piramal.com\/imaging.\n\n[\/fusion_text][fusion_separator style_type=\"none\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" top_margin=\"40px\" border_size=\"0\" alignment=\"center\" \/][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

    \u00c0 propos d'ISOLOGIC Radiopharmaceutiques Innovants<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n\nISOLOGIC Innovative Radiopharmaceuticals (ISOLOGIC) est une soci\u00e9t\u00e9 radiopharmaceutique canadienne d\u00e9di\u00e9e \u00e0 la m\u00e9decine nucl\u00e9aire et \u00e0 la science de la production radiopharmaceutique. L'engagement d'ISOLOGIC dans ces domaines comprend des centres de cyclotrons et des installations de fabrication de produits radiopharmaceutiques SPECT et PET \u00e0 travers le Canada. Utilisant une exp\u00e9rience et une expertise significatives pour fournir \u00e0 ses clients et patients des produits et services radiopharmaceutiques fiables, s\u00fbrs et de haute qualit\u00e9.\n\nLe r\u00e9seau ISOLOGIC de radiopharmacies SPECT & PET positionne l'entreprise pour desservir les organisations d'achat group\u00e9es, les syst\u00e8mes de sant\u00e9 r\u00e9gionaux, ainsi que les \u00e9tablissements de sant\u00e9 autonomes, les cliniques et les h\u00f4pitaux. Le formulaire ouvert de m\u00e9dicaments radiopharmaceutiques et d'instruments m\u00e9dicaux d'ISOLOGIC offre une flexibilit\u00e9 de choix, offrant \u00e0 ses clients un acc\u00e8s \u00e0 tous les produits radiopharmaceutiques ayant une autorisation de mise en march\u00e9 de Sant\u00e9 Canada.\n\n[\/fusion_text][fusion_separator style_type=\"none\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" top_margin=\"40px\" border_size=\"0\" alignment=\"center\" \/][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n

    Sources d'Information<\/h4>\n[\/fusion_text][fusion_text columns=\"\" column_min_width=\"\" column_spacing=\"\" rule_style=\"\" rule_size=\"\" rule_color=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" content_alignment_medium=\"\" content_alignment_small=\"\" content_alignment=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" fusion_font_family_text_font=\"\" fusion_font_variant_text_font=\"\" font_size=\"\" line_height=\"\" letter_spacing=\"\" text_transform=\"\" text_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\"]\n
      \n \t
    1. Canadian Institutes of Health Research. 2013. Alzheimer\u2019s Research in Canada. http:\/\/www.alzheimer.ca<\/li>\n \t
    2. Speechly CM, Bridges-Webb C, Passmore E. The pathway to dementia diagnosis. Med J Aust. 2008;189(9):487-9.<\/li>\n<\/ol>\n[\/fusion_text][fusion_sharing social_share_links=\"\" layout_medium=\"\" layout_small=\"stacked\" layout=\"floated\" tagline_visibility=\"show\" tagline=\"Partager\u00a0cet\u00a0article\" title=\"\" link=\"\" description=\"\" tooltip_placement=\"\" pinterest_image=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" sticky_display=\"normal,sticky\" class=\"\" id=\"\" margin_top=\"\" margin_right=\"\" margin_bottom=\"\" margin_left=\"\" wrapper_padding_top=\"\" wrapper_padding_right=\"\" wrapper_padding_bottom=\"\" wrapper_padding_left=\"\" backgroundcolor=\"\" hue=\"\" saturation=\"\" lightness=\"\" alpha=\"\" border_top=\"\" border_right=\"\" border_bottom=\"\" border_left=\"\" border_color=\"\" border_radius_top_left=\"\" border_radius_top_right=\"\" border_radius_bottom_right=\"\" border_radius_bottom_left=\"\" tagline_color=\"\" stacked_align_medium=\"\" stacked_align_small=\"center\" stacked_align=\"flex-start\" alignment_medium=\"\" alignment_small=\"space-between\" alignment=\"flex-end\" icons_boxed=\"\" icons_boxed_radius=\"\" icon_size=\"\" color_type=\"\" icon_colors=\"\" box_colors=\"\" pinterest_image_id=\"\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" icon_taglines=\"\" tagline_placement=\"after\" tagline_text_size=\"\" icon_tagline_color=\"\" icon_tagline_color_hover=\"\" separator_border_sizes=\"0\" separator_border_color=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" \/][\/fusion_builder_column][fusion_builder_column type=\"1_6\" layout=\"1_6\" spacing=\"\" center_content=\"no\" hover_type=\"none\" link=\"\" min_height=\"\" hide_on_mobile=\"small-visibility,medium-visibility,large-visibility\" class=\"\" id=\"\" background_color=\"\" background_image=\"\" background_position=\"left top\" background_repeat=\"no-repeat\" border_color=\"\" border_style=\"solid\" border_position=\"all\" padding_top=\"\" padding_right=\"\" padding_bottom=\"\" padding_left=\"\" animation_type=\"\" animation_direction=\"left\" animation_speed=\"0.3\" animation_offset=\"\" last=\"true\" border_sizes_top=\"0\" border_sizes_bottom=\"0\" border_sizes_left=\"0\" border_sizes_right=\"0\" first=\"false\"][\/fusion_builder_column][\/fusion_builder_row][\/fusion_builder_container]","_et_gb_content_width":"","footnotes":""},"categories":[11,13],"tags":[],"class_list":["post-3118","post","type-post","status-publish","format-standard","hentry","category-in-the-press","category-nouvelles-isologic"],"_links":{"self":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/posts\/3118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/comments?post=3118"}],"version-history":[{"count":0,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/posts\/3118\/revisions"}],"wp:attachment":[{"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/media?parent=3118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/categories?post=3118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/isologicradiopharm.ca\/en\/wp-json\/wp\/v2\/tags?post=3118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}